Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines

02/09/2025 32 min Temporada 6 Episodio 318
Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines

Listen "Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines"

Episode Synopsis

Two veteran biotech leaders are launching a new company with ambitions in the cardiovascular disease space. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the debut of Corsera Health, a biotech led by John Maraganore and Clive Meanwell that is developing an AI-guided early risk assessment tool alongside dual-acting therapy that could stave off heart disease.The team then discusses how FDA has been quietly positioning itself to disrupt the childhood vaccine schedule, as well as the effects of changes to the Medicare drug negotiation program that were included in the tax and budget bill Congress passed in July.View full story: https://www.biocentury.com/article/656897#Corsera #DiseaseInterception #CardiovascularHealth #HeartDisease #FDA #VaccinePolicy #Medicare #DrugPricing00:00 - Introduction01:26 - Maraganore, Meanwell Newco09:17 - BioCentury's Back to School14:51 - Vaccine Disruption at FDA26:01 - Medicare Drug NegotiationsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text